earnings
confidence high
sentiment positive
materiality 0.80
Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B
DEXCOM INC
2024-Q1 EPS reported
$0.36
revenue$921,000,000
- Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.
- Non-GAAP operating margin 15.2% (up 460 bps YoY); Non-GAAP EPS $0.32.
- FDA cleared Stelo, first OTC CGM for type 2 diabetes not on insulin; also cleared Direct-to-Watch for G7.
- Updated FY2024 revenue guidance to $4.20-4.35B (17-21% organic growth); reiterated Non-GAAP gross margin ~63-64% and operating margin ~20%.
- Cash $2.9B; revolving credit facility undrawn.